問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital

Division of Cardiovascular Diseases

更新時間:2025-08-20

陳彥舟
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

16Cases

2025-11-14 - 2031-03-30

Active
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction、 Heart Failure With Mildly Reduced Ejection Fraction Obesity

  • Test Drug

    subcutaneous injection

Participate Sites
6Sites

Not yet recruiting6Sites

2025-07-01 - 2030-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2024-03-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
21Sites

Not yet recruiting11Sites

Recruiting9Sites

2024-02-01 - 2028-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2025-03-01 - 2030-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

2025-08-01 - 2031-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-07-30 - 2028-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting8Sites

Recruiting2Sites

2025-05-01 - 2029-06-30

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-02-27 - 2030-01-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2025-09-30 - 2032-03-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

1 2